반응식
[CH3:1][N:2]1[C:7]2=[CH:8][S:9][C:10](C)=[C:6]2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14].[Cl:15][C:16]1[CH:21]=[CH:20][C:19]([C:22]2[N:23]=[C:24]([NH2:27])[S:25][CH:26]=2)=[CH:18][CH:17]=1.CCN=C=NC[CH2:34][CH2:35]N(C)C.Cl.C1C=CC2N([OH:49])N=NC=2C=1>CN(C1C=CN=CC=1)C.ClCCCl>[Cl:15][C:16]1[CH:17]=[CH:18][C:19]([C:22]2[N:23]=[C:24]([NH:27][C:34](=[O:49])[CH2:35][C:7]3[C:6]4[C:5](=[O:12])[N:4]([CH3:13])[C:3](=[O:14])[N:2]([CH3:1])[C:10]=4[S:9][CH:8]=3)[S:25][CH:26]=2)=[CH:20][CH:21]=1참가 물질
7
반응물 4
생성물 1
시약·촉매·용매 2
실험 절차
The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (200 mg, 0.709 mmol) with 4-(4-chlorophenyl)-1,3-thiazol-2-amine (149 mg, 0.709 mmol) in the presence of EDCI hydrochloride (163 mg, 0.851 mmol), HOBt (28 mg, 0.212 mmol) and DMAP (8.60 mg, 0.079 mmol) in 1,2 dichloroethane (4 ml) to give 95 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 3.19 (s, 3H), 3.47 (s, 3H), 4.06 (s, 2H), 7.07 (s, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.66 (s, 1H), 7.92 (d, J=8.4 Hz, 2H), 12.41 (br s, 1H); APCI-MS (m/z) 445.27 (M+H)+.
출처 및 근거
- ORD 기록
- ord-0abc5f82480541b2bf3ff9d23dce92f6
- 출처 데이터셋
- uspto-grants-2015_03
- 특허 번호
- US08987278B2
연결된 노트
불러오는 중…